Lupin announced that the United States Food and Drug Administration (U.S. FDA) has completed a Pre-Approval and GMP Inspection of its API manufacturing facility located in Visakhapatnam (Vizag), India. The inspection was conducted from March 6 to March 10, 2023, and concluded with no observations.

“We are pleased with the successful completion of the inspection at our Vizag facility,” said Nilesh Gupta, MD, Lupin. “This accomplishment is a testament to our commitment to upholding global quality standards across all our manufacturing sites, and to provide quality affordable healthcare for all.”